Hereditary nonpolyposis colorectal cancer medical therapy: Difference between revisions
(Mahshid) |
No edit summary |
||
Line 12: | Line 12: | ||
===Diet Optimization=== | ===Diet Optimization=== | ||
*Patients with high risk of colorectal cancer should consider a low fat diet with limitations concerning red meat. | *Patients with high risk of colorectal cancer should consider a low fat diet with limitations concerning red meat.<ref>{{Cite journal | ||
| author = [[W. C. Willett]], [[M. J. Stampfer]], [[G. A. Colditz]], [[B. A. Rosner]] & [[F. E. Speizer]] | |||
| title = Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women | |||
| journal = [[The New England journal of medicine]] | |||
| volume = 323 | |||
| issue = 24 | |||
| pages = 1664–1672 | |||
| year = 1990 | |||
| month = December | |||
| doi = 10.1056/NEJM199012133232404 | |||
| pmid = 2172820 | |||
}}</ref><ref>{{Cite journal | |||
| author = [[Jozef Kladny]] & [[Jan Lubinski]] | |||
| title = Lynch syndrome (HNPCC) | |||
| journal = [[Hereditary cancer in clinical practice]] | |||
| volume = 6 | |||
| issue = 2 | |||
| pages = 99–102 | |||
| year = 2008 | |||
| month = June | |||
| doi = 10.1186/1897-4287-6-2-99 | |||
| pmid = 19804605 | |||
}}</ref> | |||
*Dietary approaches should consider the inclusion of high fiber and rich in cellulose foods. | *Dietary approaches should consider the inclusion of high fiber and rich in cellulose foods. | ||
===Pharmacological Prevention=== | ===Pharmacological Prevention=== | ||
*Drugs lowering the risk of colorectal cancer include:<ref | *Drugs lowering the risk of colorectal cancer include:<ref>{{Cite journal | ||
| author = [[H. T. Lynch]] & [[J. Lynch]] | |||
| title = Lynch syndrome: genetics, natural history, genetic counseling, and prevention | |||
| journal = [[Journal of clinical oncology : official journal of the American Society of Clinical Oncology]] | |||
| volume = 18 | |||
| issue = 21 Suppl | |||
| pages = 19S–31S | |||
| year = 2000 | |||
| month = November | |||
| pmid = 11060321 | |||
}}</ref><ref>{{Cite journal | |||
| author = [[Matthew B. Yurgelun]] & [[Heather Hampel]] | |||
| title = Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention | |||
| journal = [[American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting]] | |||
| issue = 38 | |||
| pages = 101–109 | |||
| year = 2018 | |||
| month = May | |||
| doi = 10.1200/EDBK_208341 | |||
| pmid = 30231390 | |||
}}</ref><ref>{{Cite journal | |||
| author = [[Jozef Kladny]] & [[Jan Lubinski]] | |||
| title = Lynch syndrome (HNPCC) | |||
| journal = [[Hereditary cancer in clinical practice]] | |||
| volume = 6 | |||
| issue = 2 | |||
| pages = 99–102 | |||
| year = 2008 | |||
| month = June | |||
| doi = 10.1186/1897-4287-6-2-99 | |||
| pmid = 19804605 | |||
}}</ref> | |||
:*[[Aspirin]] | :*[[Aspirin]] | ||
:*[[Sulindac]] | :*[[Sulindac]] | ||
Line 22: | Line 75: | ||
:*[[Calcium]] | :*[[Calcium]] | ||
:*[[Vitamin C]] | :*[[Vitamin C]] | ||
The real value of | The real value of these drugs in cancer prevention in hereditary nonpolyposis colorectal cancer cannot be excluded, but is not proven. | ||
==References== | ==References== |
Revision as of 03:50, 24 January 2019
Hereditary Nonpolyposis Colorectal Cancer Microchapters |
Differentiating Hereditary Nonpolyposis Colorectal Cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hereditary nonpolyposis colorectal cancer medical therapy On the Web |
American Roentgen Ray Society Images of Hereditary nonpolyposis colorectal cancer medical therapy |
FDA on Hereditary nonpolyposis colorectal cancer medical therapy |
CDC on Hereditary nonpolyposis colorectal cancer medical therapy |
Hereditary nonpolyposis colorectal cancer medical therapy in the news |
Blogs on Hereditary nonpolyposis colorectal cancer medical therapy |
Directions to Hospitals Treating Hereditary nonpolyposis colorectal cancer |
Risk calculators and risk factors for Hereditary nonpolyposis colorectal cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
There is no medical treatment for hereditary nonpolyposis colorectal cancer.[1][2] However, hereditary nonpolyposis colorectal cancer patients should consider diet optimization and pharmacological prevention.
Medical Therapy
Patients with hereditary nonpolyposis colorectal cancer should consider the following options of medical management:[3]
Diet Optimization
- Patients with high risk of colorectal cancer should consider a low fat diet with limitations concerning red meat.[4][5]
- Dietary approaches should consider the inclusion of high fiber and rich in cellulose foods.
Pharmacological Prevention
The real value of these drugs in cancer prevention in hereditary nonpolyposis colorectal cancer cannot be excluded, but is not proven.
References
- ↑ Si JW, Wang L, Ba XJ, Zhang X, Dong Y, Zhang JX, Li WT, Li T (2015). "[Clinicopathological screening of Lynch syndrome: a report of 2 cases and literature review]". Beijing Da Xue Xue Bao (in Chinese). 47 (5): 858–64. PMID 26474631.
- ↑ Hendriks YM, de Jong AE, Morreau H, Tops CM, Vasen HF, Wijnen JT, Breuning MH, Bröcker-Vriends AH (2006). "Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians". CA Cancer J Clin. 56 (4): 213–25. PMID 16870997.
- ↑ Kladny J, Lubinski J. Lynch syndrome (HNPCC). Hered Cancer Clin Pract. 2008;6(2):99-102.
- ↑ W. C. Willett, M. J. Stampfer, G. A. Colditz, B. A. Rosner & F. E. Speizer (1990). "Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women". The New England journal of medicine. 323 (24): 1664–1672. doi:10.1056/NEJM199012133232404. PMID 2172820. Unknown parameter
|month=
ignored (help) - ↑ Jozef Kladny & Jan Lubinski (2008). "Lynch syndrome (HNPCC)". Hereditary cancer in clinical practice. 6 (2): 99–102. doi:10.1186/1897-4287-6-2-99. PMID 19804605. Unknown parameter
|month=
ignored (help) - ↑ H. T. Lynch & J. Lynch (2000). "Lynch syndrome: genetics, natural history, genetic counseling, and prevention". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18 (21 Suppl): 19S–31S. PMID 11060321. Unknown parameter
|month=
ignored (help) - ↑ Matthew B. Yurgelun & Heather Hampel (2018). "Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention". American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting (38): 101–109. doi:10.1200/EDBK_208341. PMID 30231390. Unknown parameter
|month=
ignored (help) - ↑ Jozef Kladny & Jan Lubinski (2008). "Lynch syndrome (HNPCC)". Hereditary cancer in clinical practice. 6 (2): 99–102. doi:10.1186/1897-4287-6-2-99. PMID 19804605. Unknown parameter
|month=
ignored (help)